Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease

Amino Acids

Volumn 14, Issue 1-3, 1998, Pages 75-82

  Metman, L Verhagen ^a,b   Del Dotto, P ^a   Blanchet, P J ^a   Van Den Munckhof, P ^a   Chase, T N ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Motor response complications; NMDA antagonists

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; DEXTROMETHORPHAN; DEXTRORPHAN; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ADJUVANT THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DYSKINESIA; HEART PALPITATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; META ANALYSIS; MOTOR DYSFUNCTION; NAUSEA; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL;

AMANTADINE; CLINICAL TRIALS; CONTROLLED CLINICAL TRIALS; DEXTROMETHORPHAN; DEXTRORPHAN; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; HUMANS; LEVODOPA; MOVEMENT DISORDERS; PARKINSON DISEASE; PSYCHOMOTOR PERFORMANCE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0031975428     PISSN: 09394451     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01345246     Document Type: Conference Paper

References (22)

1. Albin RL, Young AB, Penny JB (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci 12: 366-375
2. Bergman H, Wichmann T, DeLong MR (1990) Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249: 1436-1438
3. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberg F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20: 415-455
4. Blanchet PJ, Konitsiotis S, Chase TN. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord (submitted)
5. Blanchet PJ, Metman LV, Mouradian MM, Chase TN (1996) Acute pharmacologic blockade of dyskinesias in Parkinson's disease. Mov Disord 11: 580-581
6. Bresink I, Danysz W, Parsons CG, Mutschler E (1995) Different binding affinities of NMDA receptor channel blockers in various brain regions - indication of NMDA receptor heterogeneity. Neuropharmacology 34: 533-540
7. Brotchie JM, Mitchell IJ, Sambrook MA, Crossman AR (1991) Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate. Mov Disord 6: 133-138
8. Chase TN, Engber TM, Mouradian MM (1996) Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease. Adv Neurol 69: 497-501
9. Debonnel G, de Montigny C (1996) Modulation of NMDA and dopaminergic neurotrans-missions by sigma ligands: possible implications for the treatment of psychiatric disorders. Life Sci 58: 721-734
10. Dogali M, Fazzini E, Kolodny E, Eidelberg D, Sterio D, Devinsky O, Beric A (1995) Stereotactic ventral pallidotomy for Parkinson's disease. Neurology 45: 753-761
11. Engber TM, Papa SM, Boldry RC, Chase TN (1994) NMDA-receptor blockade reverses motor response alterations induced by levodopa. Neuroreport 5: 2586-2588
12. Kornhuber J, Bormann J, Hubers M, Rusche K, Riederer P (1991) Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDAreceptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol 206: 297-300
13. Kornhuber J, Schoppmeyer K, Riederer P (1993) Affinity of 1-amino-adamantanes for the sigma binding site in post-mortem human frontal cortex. Neurosci Lett 163: 129-131
14. Laitinen LV, Bergenheim AT, Hariz MI (1992) Ventroposterolateral pallidotomy can abolish all parkinsonian symptoms. Stereotact Funct Neurosurg 58: 14-21
15. Marsden C (1994) Problems with long-term levodopa therapy for Parkinson's disease. Clin Neuropharmacol 17 [Suppl 2]: S32-S44
16. Papa SM, Boldry RC, Engber TM, Kask AM, Chase TN (1995) Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res 701: 13-18
17. Papa SM, Chase TN (1996) Levodopa induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol 39: 574-578
18. Rupniak NM, Boyce S, Steventon MJ, Iversen SD, Marsden CD (1992) Dystonia induced by combined treatment with L-Dopa and MK-801 in parkinsonian monkeys. Ann Neurol 32: 103-105
19. Starr MS (1995) Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse 19: 264-293
20. Tortella FC, Pellicano M, Bowery NG (1989) Dextromethorphan and neuromodulation: old drug coughs up new activities. Trends Pharmacol Sci 10: 501-507
21. Wong BY, Coulter DA, Choi DW, Prince DA (1988) Dextrorphan and dextromethor-phan, common antitussives, are antiepileptic and antagonize N-methyl-D-aspartate in brain slices. Neurosci Lett 85: 261-266
22. Zhang Y, Britto MR, Valderhaug KL, Wedlund PJ, Smith RA (1992) Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6. Clin Pharmacol Ther 51: 647-655